Categories Analysis, Industrials

Allegiant (ALGT) may continue to take a hit from travel changes brought on by COVID-19

The company expects significant capacity cuts in May and June due to lower leisure demand trends

Like its peers in the airline industry, Allegiant Travel Company (NASDAQ: ALGT) was hit badly by the coronavirus pandemic. The company reported a 9.4% drop in operating revenues and a 42% decline in adjusted EPS. The numbers were reportedly better than what analysts had forecasted.

The company saw a slowdown in demand at the end of February followed by a sharp drop by mid-March. March revenues were down 40% year-over-year.

Based on a report by IATA, global passenger demand in 2021 is expected to be 24% below 2019 levels. The report also states that 2019 levels are not expected to be exceeded until 2023. If restrictions continue, leading to a delay in the opening of economies, global revenue passenger kilometers (RPK) in 2021 could be 34% lower than 2019 levels.   

In January, Allegiant reported a nearly 12% increase in capacity year-over-year along with a slight increase in load factor while in February, capacity rose 20.5% but load factor dipped by 1.5 points. In March, capacity fell by over 12% while load factor declined over 27 points. For the first quarter, capacity increased 4%.

Allegiant reports Q1 2020 earnings results

Allegiant reduced its April capacity by 87.4% and the company expects significant capacity cuts in May and June due to lower leisure demand trends. However, on its quarterly conference call, the company said it believes leisure travel is more likely to get back on track faster compared to international and business travel. Allegiant added that it has been seeing a slight pickup in leisure travel in recent weeks.

The company has seen a slight uptick in bookings in select markets over the past couple of weeks corresponding to the opening of beaches in Florida. Allegiant believes the next step in demand recovery is dependent on the reopening of theme parks, casino resorts and NFL stadiums in Orlando and Las Vegas, which are two of the company’s largest summer travel destinations.

The company believes international and business travel could take more time to resume as most companies have adapted to remote work and web conferencing. This could reduce the need for business meetings and other work-related travel meaningfully. The company believes these shifts could lead to a structural change in the post COVID-19 business world. It can be assumed that reduced business travel could take a meaningful toll on the company and its airline peers.

Allegiant’s main competitor Spirit Airlines (NYSE: SAVE) reported its first quarter 2020 results last week and the company saw a sharp drop in passenger demand and bookings due to the pandemic-related restrictions. The airline reduced its April capacity by around 75% while the capacity for May and June was cut by approx. 95%.  

Allegiant, meanwhile, is preparing for the worst over the coming months. The company is planning to retire around 10-15 aircraft in order to save cash. It is also looking to park as many as 10 aircraft due to softness in demand. Allegiant has also halted the construction of the Sunseeker resort indefinitely and has decided not to put any more capital into the project for at least the next 18 months.

Allegiant’s shares have fallen 53% over the past three months. The stock was up 5% in afternoon hours on Wednesday.

Most Popular

Nike (NKE) looks set to beat hurdles and build a brighter future

Nike, Inc. (NYSE: NKE) has long been ruling the sportswear market but the company had its share of problems when headwinds like the pandemic and economic slowdown hit the business

Electronic Arts (EA): A few points to keep in mind if you have an eye on this gaming company

Shares of Electronic Arts Inc. (NASDAQ: EA) stayed green on Friday. The stock has dropped 7% over the past three months. The video game industry has been facing challenges as

Petros Pharma is focused on establishing mechanisms for Rx-to-OTC switch: CCO Fady Boctor

Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) is a pharma company focused on identifying, developing, and commercializing therapeutics for men's health issues. It operates mainly through the business segments of Prescription Medications

Add Comment
Viewing Highlight